SCHEMBL3635936

SCHEMBL3635936

CC(C)(C)c1n[nH]cc1CNc1cccc(-c2ccco2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.41
EGFR P00533 1/20 0.39
AXL P30530 1/20 0.36
CLK4 Q9HAZ1 2/20 0.35
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 4/20 0.35
HPGD P15428 2/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPT P10636 5/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
ALPG P10696 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
FFAR1 O14842 1/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
CCNE2 O96020 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3636633 0.85 HDAC1 (0.44) METAP2
SCHEMBL3637488 0.79 PRMT6 (0.42) PRMT6ALDH1A1KDM4EHPGDMAPT
SCHEMBL3641235 0.78 MAOB (0.43) EGFRALDH1A1HPGDMAPTNPSR1
SCHEMBL3635913 0.78 MAPT (0.49) ALDH1A1KDM4EHPGDUSP2MAPT
SCHEMBL3637444 0.78 PRMT6 (0.41) PRMT6AXLALDH1A1HPGDMAPT
SCHEMBL3633809 0.78 METAP2 (0.40) AXLALDH1A1KDM4EHPGDMAPK1
SCHEMBL3637485 0.78 PPARG (0.36) ALDH1A1KDM4EHPGDUSP2HSD17B10
SCHEMBL3637940 0.77 MAPT (0.44) ALDH1A1KDM4EHPGDUSP2TSHR
SCHEMBL3633805 0.77 KDM4E (0.45) EGFRALDH1A1KDM4EHPGDMAPK1
SCHEMBL3640679 0.76 MAOB (0.40) ALDH1A1KDM4EHPGDMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 PRMT6 2027/4885EGFR 2738/4885AXL 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.